Key facts
- It has raised $50.0M; the latest was Early Stage VC ($50.0M) in Mar 2026.
- Notable investors include RTW Investments, Innocare, KeyMed Biosciences.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Prolium Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Prolium Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Prolium Bioscience
Operator of a clinical-stage biotechnology company intended to focus on developing novel cancer therapies. The company offers a pipeline of promising drug candidates, including bispecific antibodies for systemic sclerosis and other severe autoimmune diseases and has assembled a team with deep experience in the development of therapeutics in autoimmune disease, enabling the treatment of various cancers and improving patient outcomes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 4
- Website
- proliumbio.com/
- Ownership
- Privately Held (backing)
Prolium Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Prolium Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Prolium Bioscience in its N-PORT filings yet. We sweep new filings monthly.